U.S. pharma giant copyright scrapped two experimental weight loss products last year—a once-everyday tablet, lotiglipron, due to elevated liver enzymes and a 2 times-daily capsule, danuglipron, on account of solid Negative effects—but CEO Albert Bourla has explained the company is set to “Perform and gain” from the obesity space As well as